Save time and get answers to complex questions with AI chat
Does lipitor's use influence blood pressure medication type?Patent expiration eu dabrafenib?Defense strategy against generic in niche market?Chlorpheniramine cost?Is guselkumab off patent in u s?
See the DrugPatentWatch profile for Recarbrio
Recarbrio (imipenem/cilastatin/relebactam) was approved by the U.S. FDA on July 17, 2019. The product then launched in the U.S. later in 2019, with the initial U.S. rollout starting in late summer (roughly August–September 2019). If you’d like, I can look up the exact first sale/shipment date.
Other Questions About Recarbrio :